Cullinan Therapeutics shared new positive trial results for velinotamig in treating lupus.

Nov 9, 2026, 7:31 AM ETTrialRead the original at SEC EDGAR

Good for CGEM

Cullinan holds an exclusive license outside Greater China and reported early signs of improvement in lupus symptoms and kidney health. Only 12 patients had been treated, and results may change as the trial continues.

CGEM · Cullinan Therapeutics, Inc.

AI read · Good for CGEM

The AI's read

The results offer an early sign that Cullinan’s licensed drug may help people with hard-to-treat lupus. Kidney measures and several blood markers also improved. The trial is still small and ongoing, so later results could differ.

Get alerts for CGEM

Follow Cullinan Therapeutics, Inc. (CGEM) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for CGEM

Free on the App Store and Google Play, or on the web.